Home Blog Page 1229

Agoda Unveils Most Popular International and Domestic Destinations among Japanese Travelers for Spring Break

By
Advertorial Desk
-

― Short-haul Asian destinations remain highly popular overseas, while urban areas continue to perform strongly domestically ―

TOKYO, Feb. 20, 2026 /PRNewswire/ — Agoda Company Pte. Ltd. (Headquarters: Singapore; CEO: Omri Morgenshtern), which operates the digital travel platform Agoda, has released the latest accommodation search data on travel during the 2026 spring break period (March–April) among Japanese travelers.

The data analyzes search activity by travelers from Japan conducted between November 1, 2025, and January 13, 2026, for check-ins during March-April 2026, compared with the same period in the previous year, revealing travel demand trends ahead of the spring break season.

■ Most Popular International Destinations for Spring Break ― Short-haul Asian destinations offer highly satisfying trips, even for shorter stays ― 

＜Top 5 International Destinations＞ 

1st: Seoul, South Korea, 2nd: Taipei, Taiwan, 3rd: Bangkok, Thailand, 4th: Busan, South Korea, 5th: Hong Kong

For international travel, Seoul, South Korea, emerged as the most searched destination during the spring break period among Japanese travelers. In addition to its convenient access from Japan, Seoul offers a rich mix of gourmet dining, shopping, and cultural experiences, making it a highly favored destination for short overseas trips. In particular, the city is seeing growing popularity among solo travelers, especially those traveling for beauty and wellness purposes.

Taipei, Taiwan, is known for its approachable food culture and walkable city layout, making it an attractive choice for first-time international travelers or those returning overseas after some time. The ease of enjoying night markets and local cuisine contributes to higher satisfaction for spring break travel.

Bangkok, Thailand, is characterized by its combination of urban sightseeing and resort elements, offering a wide range of experiences including shopping, spas, and gourmet dining. The city continues to attract travelers who use relatively longer holidays to plan trips that combine city stays with nearby resort destinations.

Busan, South Korea, is appreciated for its unique blend of coastal scenery and urban landscapes. Activities such as café hopping and seaside walks appeal to travelers seeking a more relaxed pace, while the opportunity to experience a different side of Korea compared to Seoul also contributes to its popularity.

Hong Kong maintains steady popularity as a short-term spring break destination, offering diverse attractions that range from gourmet dining and shopping to nature and art. The ability to enjoy a wide variety of experiences efficiently within a limited schedule makes Hong Kong a strong match for spring break travel.

■ Most Popular Domestic Destinations for Spring Break ― Urban sightseeing and seasonal experiences, centered around Tokyo, remain highly popular ― 

＜Top 5 Domestic Destinations＞ 

1st: Tokyo, 2nd: Osaka, 3rd: Sapporo, 4th: Fukuoka, 5th: Okinawa Main Island

For domestic travel, Tokyo continues to rank as the most searched destination for the spring break period. The city is highly regarded for offering a wide variety of experiences even during short stays, including the latest gourmet dining, shopping, and entertainment, as well as cherry blossom viewing spots and spring-only events. The ability to enjoy both urban sightseeing and a strong sense of seasonality continues to support Tokyo’s stable popularity as a spring break destination.

Osaka is valued for its vibrant food culture and high level of entertainment, including theme parks, and benefits from convenient access to nearby cities such as Kyoto and Kobe. As a result, Osaka is often selected as a base for travelers planning to explore the wider Kansai area.

Sapporo is characterized by its balance between urban convenience and proximity to nature, with travelers drawn to seasonal Hokkaido cuisine and the changing scenery as winter transitions into spring. For those seeking to experience seasonal shifts, Sapporo remains an appealing option for spring break travel.

Fukuoka is appreciated for its compact urban layout, which allows travelers to efficiently enjoy gourmet dining, shopping, and sightseeing. Serving as a key gateway to destinations across Kyushu, the city supports travel itineraries that combine urban stays with regional exploration, further driving spring break demand.

Okinawa Main Island continues to attract travelers seeking an escape from everyday life during the spring break season. With a calmer atmosphere ahead of the summer peak, visitors can enjoy a well-balanced mix of nature, culture, and activities.

In addition, year-on-year growth in travel interest was observed for cities such as Nagoya, Yokohama, Hiroshima, Sendai, and Chiba, indicating rising attention toward core regional cities that offer both convenient transportation access and ease of urban sightseeing.

Tadashi Ikai, Senior Country Director, Japan at Agoda, shared, “Spring break is a key travel season, with a wide range of travelers—from students to working professionals—planning trips during this period. Agoda’s search data shows that internationally, short-haul Asian destinations continue to maintain strong popularity, while domestically, urban areas led by Tokyo remain steady favorites. Agoda will continue to offer a wide selection of accommodations at great value, enabling travelers to enjoy highly satisfying trips even within limited vacation time.”

Travelers can seamlessly search and book more than 6 million accommodations, 130,000+ flight routes, and 300,000+ activities through Agoda’s platform. Attractive accommodation deals can be easily found via the Agoda mobile app or official website (Agoda.com).

Transforming Knee Surgery: Columbia Asia Combines Expertise and Robotics for Better Outcomes

By
Advertorial Desk
-

JOHOR BAHRU, MALAYSIA – Media OutReach Newswire – 20 February 2026 – Columbia Asia Hospital Tebrau is advancing patient-centred knee care by offering a full continuum of treatment for osteoarthritis, ranging from Hyaluronic Acid (HA) injections to state-of-the-art robotic-assisted total knee replacement (TKR).

Columbia Asia Hospital Tebrau Poster Hospital [TKR]

“Our knees are subjected to wear and tear over time due to aging, injuries, and repetitive stress,” said Dr Hazli Sufian, Consultant Orthopedic Surgeon with Special Interest in Arthroplasty at Columbia Asia Hospital Tebrau. “While HA injections can help relieve pain and improve mobility in early-stage osteoarthritis, advanced cases often require knee replacement surgery for long-term relief and function.”

Dr Hazli and his surgical team have replaced conventional techniques with the CORI® robotic-assisted system by Smith+Nephew, an advanced technology designed to enhance precision and personalise knee replacement procedures.

“The CORI® system allows surgeons to capture patient-specific anatomical data in real time, enabling more precise bone preparation and soft tissue balancing,” Dr Hazli explained. “This contributes to improved joint stability, better alignment, and more natural knee movement after surgery.”

Beyond surgical precision, robotic-assisted technology improves the overall patient experience. The personalised approach can lead to reduced tissue disruption, less post-operative pain, and lower risk of complications. Many patients also benefit from enhanced mobility, greater confidence in joint function, and a potentially faster return to daily activities and rehabilitation.

By tailoring each procedure to the patient’s unique anatomy, the CORI® system supports predictable outcomes and consistent surgical results, which are key to long-term patient satisfaction.

Dr James Chong, CEO of Columbia Asia Hospital Tebrau, said the introduction of robotic-assisted knee replacement reflects the hospital’s commitment to advancing patient-centred care through innovation.

“Our investment in robotic-assisted surgery enhances not only surgical precision but also the overall patient journey—from pre-operative planning and intra-operative accuracy to post-operative recovery and rehabilitation,” he said. “This technology allows us to deliver high-quality outcomes while improving comfort, confidence, and experience for our patients.”

Hashtag: #ColumbiaAsiaHospitalTebrau #RightHereForYou #MalaysiaPRAwards2025 #PRCA #HealthcareExcellence #TeamTebrau #CommunityCare #HospitalCommunications #AwardWinningTeam #TotalKneeReplacement #RoboticTotalKneeReplacement






The issuer is solely responsible for the content of this announcement.

About Columbia Asia Hospital Tebrau

Columbia Asia Hospital Tebrau is dedicated to serving the healthcare needs of the Johor community with compassion, professionalism, and clinical excellence. Equipped with advanced medical technology—including a Cardiac Catheterization Laboratory, Mammography services, a 128-slice CT Scan, and a 1.5 Tesla MRI—the hospital delivers comprehensive diagnostic and treatment capabilities to support timely and accurate clinical decision-making.

The hospital offers a broad range of medical specialties, including Cardiology, Nephrology, Internal Medicine, Maternal Fetal Medicine, Ear, Nose & Throat (ENT), General Surgery, Obstetrics & Gynecology (O&G), Respiratory Medicine, Orthopaedics, and Dermatology. A fully operational 24/7 Emergency Room, supported by on-call Emergency Physicians, ensures that patients receive immediate and appropriate care at any time of the day.

At the core of Columbia Asia Hospital Tebrau’s philosophy is a strong commitment to personalized, patient-centred care—ensuring that every individual feels heard, supported, and well cared for throughout their healthcare journey.

Looking ahead over the next five years, Columbia Asia Hospital Tebrau will align its strategic direction with Rancangan Malaysia Ke-13 (RMK-13), with a focused emphasis on addressing Non-Communicable Diseases (NCDs). In particular, the hospital will strengthen its efforts in obesity management through integrated, multidisciplinary care models encompassing prevention, early intervention, medical management, surgical intervention and long-term follow-up. This reflects a proactive approach to tackling one of the most pressing public health challenges affecting the Johor community.

In parallel, the hospital has advanced its surgical capabilities through the adoption of robotic-assisted surgery. This investment is aimed at enhancing surgical precision, improving clinical outcomes, reducing recovery times, and elevating overall patient experience, in line with global best practices.

To meet the growing healthcare demands of Johor, Columbia Asia Hospital Tebrau is also planning for future expansion, including the addition of more inpatient beds. This expansion will enable the hospital to better serve the increasing needs of the community while maintaining high standards of safety, quality, and accessibility in care delivery.

Through strategic alignment, technological advancement, and capacity expansion, Columbia Asia Hospital Tebrau remains committed to supporting the long-term health and well-being of the Johorean population.

About Columbia Asia

For 30 years, Columbia Asia Group of hospitals has been at the forefront of quality healthcare in the private healthcare industry. Established in 1996, it has evolved from its first hospital in Shah Alam to its latest in Penang, to date. As an international healthcare provider, its services span across 19 hospitals in the region; 13 in Malaysia, five in Indonesia, and one in Vietnam. Through the years, the company strategy has always been about making private healthcare accessible to all, hence its hospitals are strategically located in densely populated areas. Under the umbrella of private healthcare company, Asia OneHealthcare, the Columbia Asia group has expanded its reach to bring not just world-class, but also effective healthcare, closer to home.

Through the years, Columbia Asia’s emphasis has consistently been about early detection of diseases. This is carried out by way of advanced technology for precise diagnostics, resulting in minimally invasive procedures. To fulfil the typical healthcare needs of communities, Columbia Asia offers core disciplines such as obstetrics & gynecology, pediatrics, and general surgery. Today, it also provides tertiary healthcare addressing more complex fields of medicine such as neurosurgery, cardiac disease treatments, and integrated cancer care.

As it approaches a new decade, Columbia Asia continues to expand; adopting cutting-edge technology to meet the ever-increasing needs of today’s discerning customers. Upholding strict clinical governance, medical ethics and acknowledged by the Malaysian Society for Quality in Health, Columbia Asia continues to deliver excellent patient outcomes in a safe and trusted environment.

Columbia Asia. Right Here For You.

FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

By
Advertorial Desk
-

MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces its financial results for the year ended December 31, 2025.

FY 2025 key results1

Group performance2: Double-digit revenue growth and positive adjusted operating cash flow

  • Revenue of US$803.8 million, up by 56%3 and achieving upsized full year guidance4.
  • US$157.1 million invested in research and development (R&D) product development for late-stage therapeutics and precision medicine pipeline assets5, in line with stated FY 2025 guidance.
  • Adjusted EBITDA6 of US$39.5 million, reflective of increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure and research and development (R&D).
  • A non-material loss before tax of US$5.3 million, includes US$26.7 million in non-cash finance costs associated with convertible bonds and increased asset amortization of US$11.9 million (2024: US$5.1 million) following the RLS Radiopharmacies (RLS) acquisition.
  • Year-end cash balance of US$141.9 million following US$246.4 million of strategic investments (M&A) and cash generated from operating activities of US$34.5 million before the final contingent consideration payment to Advanced Nuclear Medicine Ingredients (ANMI) of US$51.8 million7.

Telix Precision Medicine: Strengthening commercial profitability, driving growth

  • Precision Medicine segment revenue up by 22% year-over-year, driven by continued increase in Illuccix® volumes and successful launch of Gozellix® in the U.S.
  • Gross margin remains stable at 64%.
  • Adjusted (segment) EBITDA up by 24% year-over-year to US$216.4 million.
  • Selling and marketing expenses of US$82.4 million, reflecting incremental investment in global commercial infrastructure for new product launches (Illuccix EU, Gozellix, Zircaix®8 and Pixclara®8).
  • TLX101-Px (Pixclara8) regulatory filings: Telix has filed a marketing authorization application for TLX101-Px in Europe, concurrent to finalizing the New Drug Application (NDA) package for the U.S. Food and Drug Administration (FDA).
  • TLX250-Px (Zircaix8) submission: Based on the two Type A meetings with the FDA, Telix believes it has aligned on key outstanding issues for the Biologics License Application (BLA) resubmission, including demonstration of drug product comparability between clinical trial material and scale-up commercial production. The Company is now completing the agreed deliverables and documentation required for resubmission.

Telix Manufacturing Solutions (TMS): Expanded global operations to deliver patient outcomes

  • TMS segment includes RLS, IsoTherapeutics (TX, U.S.), and production (and R&D) facilities in Sacramento (CA, U.S.), Brussels (Belgium), North Melbourne (Australia) and Yokohama (Japan), representing a significantly expanded global production and manufacturing footprint.
  • RLS reported US$238.4 million of total segment revenue, which includes US$170.1 million from third-party product sales and service fees, and US$68.3 million inter-segment revenue9, reflecting excellent growth in sales of Illuccix and Gozellix through the RLS network. 
  • RLS transitioned to positive adjusted EBITDA contribution of US$1.2 million.
  • RLS operating loss includes US$7.4 million of depreciation and amortization on acquired intangibles.
  • Adjusted EBITDA loss for the TMS segment of US$21.7 million, expenditure consistent with first half, demonstrating inter-company cost control (H1 2025: Adjusted EBITDA loss of US$12.7 million).

Telix Therapeutics: Prioritization of R&D investment towards advancing late-stage assets

Of the total R&D investment, US$98.0 million was invested in the therapeutics pipeline. Milestones achieved include:

  • TLX591-Tx (lutetium (177Lu) rosopatamab tetraxetan): Completed target enrollment of 30 patients for Part 1 of the ProstACT® Global10 Phase 3 study in metastatic castration resistant prostate cancer (mCRPC). First patients treated in Part 2 (randomized expansion)11.
  • TLX250-Tx (177Lu-DOTA-girentuximab): Received regulatory approval to commence LUTEON12, a global Phase 2/3 monotherapy trial in metastatic clear cell renal cell carcinoma (ccRCC), initiating sites. First patients dosed in the STARLITE-113 Phase 1b/2 investigator-initiated trial exploring TLX250-Tx in combination with cabozantinib and nivolumab in ccRCC.
  • TLX101-Tx (iodofalan 131I): Received regulatory approval in Australia and the European Union to commence the IPAX-BrIGHT14 pivotal trial of TLX101-Tx in recurrent glioblastoma (GBM).
  • TLX592-Tx (225Ac-PSMA-RADmAb): Received regulatory approval to commence AlphaPRO15, a Phase 1, first-in-human (FIH) study of Telix’s targeted alpha therapy (TAT) candidate in advanced mCRPC.
  • TLX252-Tx (225Ac-DOTA-girentuximab): Received regulatory approval to commence ALPHIX16, a Phase 1, FIH study of Telix’s TAT candidate for the treatment of patients with advanced metastatic kidney cancer and other carbonic anhydrase IX (CAIX) expressing cancers.
  • TLX300-Px (89Zr-olaratumab): First patients dosed in the ZOLAR17 Phase 1, FIH imaging study for patients with advanced, metastatic soft tissue sarcoma (STS) and other platelet derived growth factor receptor alpha (PDGFRα) positive tumors, aiming to demonstrate proof of concept for therapy.
  • TLX090-Tx (153Sm-DOTMP): First U.S. patients dosed in SOLACE18, a Phase 1 study evaluating safety, dosimetry, patient‑reported outcomes, and potential opioid‑sparing effects of TLX090‑Tx in patients with metastatic bone pain.

FY 2026 Guidance

  • Telix provides FY 2026 Group Revenue guidance of US$950 million to US$970 million. 
  • Guidance reflects revenue from product sales in jurisdictions with a marketing authorization, and a full year of revenue contribution from RLS.
  • Telix provides pipeline R&D expenditure guidance of US$200 million to US$240 million.

Executive Commentary

Managing Director and Group CEO, Dr. Christian Behrenbruch, commented on the result: “Our strong commercial performance in 2025 provides a platform for continued growth across Telix’s global Precision Medicine franchise. The revenue guidance we are issuing today reflects our confidence in sustaining the momentum of our core cash generative business. Consistent with our stated strategy, we are reinvesting earnings to prioritize the acceleration of our best-in-class therapeutic pipeline, which now includes three pivotal stage trials in prostate, kidney and brain cancer. We also intend to continue to expand the Precision Medicine growth opportunity through label expansion studies and new product launches. In 2026 we are focused on delivery of these near‑term priorities to further strengthen the foundations for long‑term revenue and earnings growth.”

Summary: Group financial results

2025

2024

US$M

US$M

Revenue

803.8

516.6

Cost of sales

(377.4)

(180.4)

Gross profit

426.4

336.2

Research and development

(171.2)

(127.9)

Selling and marketing

(96.8)

(56.0)

Manufacturing and distribution

(44.6)

(16.7)

General and administration

(95.7)

(85.3)

Other gains (net)

11.7

4.9

Operating profit

29.8

55.2

Finance income

5.8

7.2

Finance costs

(40.9)

(24.4)

(Loss)/profit before income tax

(5.3)

38.0

Adjusted EBITDA19

39.5

66.9

Cash (used in)/from operating activities

(17.3)

27.5

 

Investor call

An investor webcast and conference call will be held at 9:30 a.m. AEDT on Friday 20 February 2026 (5:30 p.m. EST Thursday 19 February 2026).
Participants can register for the webcast or the teleconference by clicking here: https://edge.media-server.com/mmc/p/famdpwzh

To read or download the 2025 Annual Report and to view the accompanying investor presentation, visit Telix’s Investor Relations website: ir.telixpharma.com/

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Canada, Europe (Belgium and Switzerland), Brazil and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA.

Telix’s osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix’s miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. No other Telix product has received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations (Global)

Ms. Kyahn Williamson

SVP Investor Relations and Corporate Communications

kyahn.williamson@telixpharma.com

Telix Investor Relations (Australia)

Ms. Charlene Jaw

Associate Director Investor    Relations

charlene.jaw@telixpharma.com

Telix Investor Relations (U.S.)

Ms. Annie Kasparian

Director Investor Relations and Corporate Communications

annie.kasparian@telixpharma.com

Guidance Disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its commercial products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Non-IFRS Financial Measures. Telix’s results are reported under International Financial Reporting Standards (IFRS). This announcement includes various non-IFRS financial information to reflect its underlying performance, which have not been subject to audit or review. These non-IFRS measures include Adjusted EBITDA, which represents net earnings attributable to the Group excluding net finance costs, income tax expense, depreciation and amortization and other gains/(losses) (net). As required by SEC rules, we have provided reconciliations of these non-IFRS financial measures to the most directly comparable IFRS measures, which for Adjusted EBITDA, is Profit/(loss) before income tax. The Group believes that these non-IFRS measures, which are not considered to be a substitute for or superior to IFRS measures, provide stakeholders with additional useful information on the underlying trends, performance and position of the Group and are consistent with how business performance is measured internally. The non-IFRS measures are not defined by IFRS and therefore may not be directly comparable with other companies’ alternative performance measures.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

[1] See summary Group financial results table at end of this document.

[2] Group performance includes Telix Precision Medicine, Telix Therapeutics and Telix Manufacturing Solutions (TMS).

[3] All comparisons to FY 2024 results.

[4] Revised FY 2025 revenue guidance of US$800 million to US$820 million.

[5] US$14.1 million of inventory for TLX250-Px (Zircaix®) commercial launch is additionally expensed to R&D. This expense arises from commercial inventory produced in anticipation of Zircaix approval and will be reversed upon FDA approval if received.

[6] Earnings before interest, tax, depreciation and amortization.

[7] In 2018, Telix acquired ANMI, the developer of the underlying Illuccix technology. The acquisition agreement included contingent consideration (variable payments) based on Illuccix global sales for five years following marketing authorization of Illuccix, with an option to buy out remaining payments in the third year following marketing authorization if agreed sales thresholds were met. As a result of strong sales performance, Telix successfully exercised its option to buy-out the remaining variable payments. The final payment of US$51.8 million comprising the option payment and third and final annual variable payment was made in July 2025, and is reflected in the cash flows for H2 2025, included in the Company’s full year financial results.

[8] Launch and brand names subject to final regulatory approval.

[9] Inter-segment revenue is eliminated on consolidation, refer to note 3 of the financial statements lodged today with the ASX.

[10] Telix ASX disclosure August 21, 2025. ClinicalTrials.gov ID: NCT06520345.

[11] Telix media release December 8, 2025.

[12] ClinicalTrials.gov ID: NCT07197580.

[13] ClinicalTrials.gov ID: NCT05663710.

[14] ClinicalTrials.gov ID: NCT07100730.

[15] Telix ASX disclosure August 21, 2025.

[16] Telix ASX disclosure January 20, 2026.

[17] Telix media release April 2, 2025. ClinicalTrials.gov ID: NCT06537596.

[18] Telix media release October 23, 2025. ClinicalTrials.gov ID: NCT07197645.

[19] Earnings before interest, tax, depreciation and amortization and other gains/(losses) (net).

/C O R R E C T I O N — Republic Power Group Limited (NASDAQ: RPGL)/

By
Advertorial Desk
-

In the news release, ” Republic Power Group Limited Announces 1-For-20 Reverse Share Split”, issued on February 20, 2026 by Republic Power Group Limited over PR Newswire, we are advised by the company that the market effective date of the reverse share split should be February 24, 2026, rather than February 23, 2026, as originally issued inadvertently. Complete, corrected release follows:

Republic Power Group Limited Announces 1-For-20 Reverse Share Split

SINGAPORE, Feb. 20, 2026 /PRNewswire/ — Republic Power Group Limited (NASDAQ: RPGL), today announced that it will effect a reverse share split of its Class A ordinary shares, par value $0.000625 per share (the “Class A Ordinary Shares”) and Class B ordinary shares, par value $0.000625 per share (the “Class B Ordinary Shares”), at a ratio of 1-for-20, to be effective at the open of business on February 24, 2026.

Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market (“Nasdaq”) on February 24, 2026. There is no public market for our Class B Ordinary Shares. Following the reverse share split, the Class A Ordinary Shares will have a new par value of $0.0125 per share and will continue to trade on Nasdaq under the symbol “RPGL” with the new CUSIP number, G7523E113. The reverse share split is expected to lead the Company’s Class A Ordinary Shares to trade at approximately 20 times the price per share at which it trades prior to the effectiveness of the reverse share split. The Company, however, cannot assure that the price of its Class A Ordinary Shares after the reverse split will reflect the 1-for-20 reverse split ratio, that the price per share following the effective time of the reverse split will be maintained for any period of time, or that the price will remain above the pre-split trading price. The reverse share split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per Class A Ordinary Share for continued listing on Nasdaq.

No fractional shares will be issued in connection with the reverse share split and all such fractional interests will be rounded up to the nearest whole number of Class A Ordinary Shares.

The reverse share split will reduce the number of issued and outstanding shares of the Company’s Class A Ordinary Shares from 62,025,000 to approximately 3.1 million shares, subject to any adjustments resulting from the treatment of the fractional shares.

On February 2, 2026, the board of directors of the Company approved the reverse share split of the Class A Ordinary Shares and Class B Ordinary Shares, at a ratio of 1-for-20.

Transhare Corporation is acting as the exchange agent and paying agent for the reverse share split. Shareholders holding their shares in book-entry form or in brokerage accounts need not take any action in connection with the reverse share split.

Transhare Corporation will provide instructions to any shareholders with certificates regarding the process in connection with the exchange of pre-reverse share split share certificates for ownership in book-entry form or share certificates on a post-reverse share split basis. Shareholders are encouraged to contact their bank, broker or custodian with any procedural questions.

About Republic Power Group Limited

Republic Power Group Ltd. is a Singapore-based company engaged in developing customized enterprise resource planning (“ERP”) software solutions, consulting and technical support services, and peripheral hardware.

For more information on our latest innovations and developments, visit https://republicpower.net/.   

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company’s goals and strategies; the Company’s future business development; the Company’s future acquisition opportunities; the Company’s ability to identify any acquisition opportunities that fit with our business strategies; the Company’s ability to consummate an attractive acquisition and realize the benefits of such transaction; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

 

Evolving forward as Elicron

By
Advertorial Desk
-

STOCKHOLM, Feb. 20, 2026 /PRNewswire/ — Building on the merger of Permascand and Magneto Special Anodes, the company now enters a new chapter as Elicron. The new name reflects a strong legacy and an ambition to support customers’ operational excellence in evolving markets.

A year ago, Permascand merged with Magneto Special Anodes, establishing a leading global position in electrochemical solutions specializing in high end coted anodes and cathodes. Looking ahead, the ambition is to continue growing with solutions that enables customers operational excellence.

To mark this new chapter, the company moves forward under the name Elicron. The name combines “Electrochemical” and “On”, capturing the essence of the company’s expertise and ambitions.
Short and memorable, it connects a strong legacy with a clear ambition to create long-term value in established and new markets.

“Elicron reflects what we work with every day and gives our shared technical expertise a distinct and unified expression. Together, Permascand and Magneto have 125 years of experience that our customers can truly benefit from,” says David Ekberg, CEO of Elicron.

Elicron’s manufacturing sites and R&D operations are in three different continents: Europe, North America and Asia. Across this global organization of around 350 specialists, Elicron brings together a unique depth of expertise that is critical to shaping the future of advanced electrochemical solutions.

As the world moves towards cleaner, more efficient and resilient systems, Elicron supports this transition by manufacturing advanced electrochemical components, upgrading existing installations and co-developing durable, high-performance solutions. Elicron’s mission is to create long-term business value while at the same time reducing environmental impact.

“Our journey ahead will be defined by initiative, curiosity and the innovative spirit that has long characterized both Permascand and Magneto Special Anodes. Elicron embodies stability and a confident future for our clients around the world,” David Ekberg continues.

CONTACT:

For more information, please contact:
David Ekberg, CEO, +4676-146 03 27 or david.ekberg@permascand.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/elicron/r/evolving-forward-as-elicron,c4308797

The following files are available for download:

 

White Pearl Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Rights Commencing February 24, 2026

By
Advertorial Desk
-

NEW YORK, Feb. 20, 2026 /PRNewswire/ — White Pearl Acquisition Corp. (NYSE: WPAC U) (the “Company”) today announced that, commencing February 24, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and rights included in the units.

No fractional rights will be issued upon separation of the units and only whole rights will trade. The Class A ordinary shares and rights that are separated will trade on The New York Stock Exchange under the symbols “WPAC” and “WPAC RT” respectively. Those units not separated will continue to trade on The New York Stock Exchange under the symbol “WPAC U.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A ordinary shares and rights.

A registration statement on Form S-1 (File No. 333-290905) (the “Registration Statement”) relating to the securities sold in the initial public offering, as amended, was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on January 30, 2026. The offering was made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from D. Boral Capital LLC at 590 Madison Avenue, 39th Floor, New York, NY 10022, by telephone at (212) 970-5150 or by email at info@dboralcapital.com or by accessing the SEC’s website, www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About White Pearl Acquisition Corp.

White Pearl Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. White Pearl Acquisition Corp. intends to focus on businesses in the financial technology (FinTech), information technology (InfoTech) and business service sectors.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the anticipated use of the net proceeds and search for an initial business combination. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.

 

Indian, Regional, and Global Partners Launch Initiatives to Address Extreme Heat in South Asia

By
Advertorial Desk
-

The World Health Organization (WHO)–World Meteorological Organization (WMO) Climate and Health Joint Programme, The Rockefeller Foundation, and Wellcome announce new regional efforts to connect climate science to health action to prevent heat impacts, help communities flourish, and save lives.

MUMBAI, India, Feb. 20, 2026 /PRNewswire/ — At Mumbai Climate Week, the WHO-WMO Climate and Health Joint Programme, The Rockefeller Foundation, and Wellcome announced two new integrated initiatives to protect South Asians from extreme heat – a rapidly escalating threat to human health and economic stability in the subcontinent.

The two new initiatives, funded by The Rockefeller Foundation and Wellcome, will strengthen South Asia’s ability to detect, prepare for, and respond to extreme heat and other weather- and climate-related health impacts.

The South Asia Climate–Health Desk, established as part of the WHO–WMO Climate and Health Joint Programme and implemented with the Indian Institute of Tropical Meteorology (IITM), India Meteorological Department (IMD), and other partners will improve how climate and weather information is translated into action to protect health.

Complementing this work, the South Asia Scientific Research Consortium, supported through a Rockefeller Foundation grant to the Indian Institute of Science Education and Research (IISER) Pune, will deepen the region’s scientific understanding of how heat affects different populations. These projects are the first two components of a broader, more ambitious regional strategy to address extreme heat risks to health. As part of a growing suite of Joint Programme initiatives, including regional activities of the Global Heat Health Information Network, these are first steps of coordinated science-driven efforts to protect communities, with more updates on the broader rollout coming soon.

“Extreme heat is a growing risk for lives and livelihoods in South Asia,” said Dr. Mrutyunjay Mohapatra, IMD’s Director General of Meteorology and Permanent Representative of India to WMO. “IMD welcomes this partnership with IITM under the South Asia Climate-Health Desk, which will strengthen the science-to-services pathway, improve early warning support for health, and help decision-makers act in time to protect communities during severe heat events.”

UN Secretary-General António Guterres has called for urgent global action to address the growing risk of extreme heat worldwide, which takes a heavy toll on health in South Asia – the world’s most populated region. According to WMO, Asia is warming nearly twice as fast as the global average, intensifying extreme weather and placing growing pressure on lives and livelihoods, health systems, economies, and ecosystems across the region, putting the most vulnerable and exposed communities at critical risk.

In India and Pakistan, pre-monsoon temperatures regularly rise above 50°C, and heat-related mortality in the region today exceeds 200,000 deaths per year. At the same time, extreme heat undermines economic stability and productivity. In 2024 alone, heat exposure in India led to 247 billion potential labor hours lost – reducing labor capacity and leading to an estimated $194 billion loss in income, according to the Lancet Countdown.

“Few regions feel the impacts of extreme heat as sharply as South Asia, and I welcome the clear determination to respond. We all know that every death primarily due to excess heat can be prevented and heat health action plans are saving lives,” said Professor Celeste Saulo, Secretary-General of the World Meteorological Organization. “By uniting science, government leadership and support, and community action, countries here are proving that this challenge can be met.”

Addressing extreme heat requires coordinated, transdisciplinary action. This integrated effort equips governments, public services, communities, and health systems with the actionable knowledge they need to prevent avoidable illness and save lives. The two coalition initiatives include:

  1. South Asia Climate–Health Desk: Led by IITM in partnership with IMD, this new unit will help meteorological institutions and health partners in South Asia work closely together to develop more robust decision support tools, such as early warning and risk assessments. Representing one of the first units to be launched as part of the Joint Programme spanning Research and Development (R&D) and operational domains in climate and health, it will strengthen the ability of a wide range of stakeholders to co-develop, validate, and share health‑relevant and fit-for-purpose weather and climate information, so communities, health authorities, and health services can build resilience and act quickly before and during dangerous heat events and other climate-related health risks including disease outbreaks.
  2. South Asia Scientific Research Consortium: Led by IISER Pune, this consortium of research institutions, including MS Swaminathan Research Foundation and IITM, will deepen understanding of how heat affects people across South Asia—depending on where they live, the work they do, and the different conditions they face. By developing tailored heat‑risk thresholds, this consortium aims to ultimately strengthen heat action planning, early warning systems, and preparedness efforts, helping communities and institutions better adapt to rising temperatures in one of the world’s most heat-vulnerable regions.

This announcement is the first in a series of rollouts planned in 2026, highlighting work being carried out in the region. The Rockefeller Foundation and Wellcome’s US $11.5 million investment in the WHO-WMO Climate and Health Joint Programme aims to expand climate‑informed health action in vulnerable regions. The two philanthropies committed the funds to pioneer new models of science-driven collaboration between health partners and meteorological departments, aiming to bridge a gap that often leaves health systems without critical climate information that can protect communities and save lives.

Through the establishment of these initiatives, South Asia is leading the way in implementing this integrated climate and health approach that connects research, climate monitoring and forecasting, and health responses to protect people from the health risks of climate variability and change.

“After a decade of punishing and increasingly deadly heatwaves across India and the wider South Asia region, it’s clear that business‑as‑usual public health approaches are no longer enough. Protecting India’s most vulnerable communities requires rethinking how we deliver care and invest in the solutions frontline providers and patients urgently need today,” said Dr. Naveen Rao, Senior Vice President of Health at The Rockefeller Foundation. “Through our support to the Joint Programme, we aim to help turn cutting‑edge science into real‑world impact, helping India and the region build a resilient, climate‑ready health system fit for the 21st century.”

“Rising temperatures due to climate change are a public health threat, endangering people’s lives and livelihoods throughout the world. In South Asia, extreme heat is hitting communities hard – in particular children, pregnant people, older people, outdoor workers and those communities with the least resources to respond,” said Dr. Alan Dangour, Director of Climate and Health at Wellcome. “We need to invest in science-led solutions that both cut emissions and build resilience, with public health at the core of decision-making. Wellcome is proud to work with partners and communities across South Asia to develop the evidence, tools and solutions that will ultimately improve health and save lives.”

About the Partners and Funders:

WHO-WMO Climate and Health Joint Programme
Through their Joint Programme, the World Meteorological Organization (WMO) and the World Health Organization (WHO) work together to help countries protect health in a changing climate. The Joint Programme supports Member States and partners to improve the application of climate, weather, and environmental information in public health decision-making by strengthening collaboration, building technical capacity, and promoting the use of climate and environmental data to protect health and save lives.
www.climahealth.info

Indian Institute of Tropical Meteorology (IITM)
IITM is India’s premier centre for atmospheric and climate research and an autonomous institute under the Ministry of Earth Sciences, Government of India. It advances scientific understanding of monsoon systems, extreme weather, air quality, and the ocean–atmosphere climate system, providing the foundation for better forecasts and climate‑resilient planning. IITM’s work supports sectors from agriculture to urban management and plays a central role in strengthening India’s preparedness for heatwaves and other climate‑driven risks.
https://www.tropmet.res.in/ 

Indian Institute of Science Education and Research (IISER)
IISER Pune is a premier public research institute and Institution of National Importance dedicated to advancing interdisciplinary science. Established in 2006, it integrates world‑class research with high‑quality education across disciplines including biology, chemistry, physics, earth and climate sciences, and mathematics. IISER Pune fosters scientific innovation, trains the next generation of researchers, and contributes cutting‑edge insights that support India’s resilience to climate and environmental challenges.
https://www.iiserpune.ac.in/ 

India Meteorological Department (IMD)
IMD, established in 1875, is the India’s official weather and climate agency and a cornerstone of the country’s disaster preparedness and climate resilience. As the National Meteorological Service under the Ministry of Earth Sciences, Government of India, IMD provides real‑time observations, climate data and monitoring, forecasts, and early warnings for hazards such as cyclones, heatwaves, heavy rainfall, and storms, supporting critical sectors from agriculture and aviation to public health and emergency management. Its science, data, and nationwide network help safeguard lives and guide climate‑smart development across India.
https://mausam.imd.gov.in/ 

The Rockefeller Foundation
Investing $30 billion over the last 113 years to promote the well-being of humanity, The Rockefeller Foundation is a pioneering philanthropy built on unlikely partnerships and innovative solutions that deliver measurable results for people in the United States and around the world. We leverage scientific breakthroughs, artificial intelligence, and new technologies to make big bets across energy, food, health, and finance, including through our public charity, RF Catalytic Capital (RFCC). For more information, sign up for our newsletter at www.rockefellerfoundation.org/subscribe and follow us on X @RockefellerFdn, Instagram @rockefellerfdn, and LinkedIn @the-rockefeller-foundation.
https://www.rockefellerfoundation.org/ 

Wellcome
Wellcome is a global charitable foundation that supports science and innovation to tackle the world’s most urgent health challenges facing everyone. They support discovery research into life, health and wellbeing, and are taking on three worldwide health challenges: mental health, infectious disease and climate and health. Its climate and health work puts people’s health at the centre of climate action—building research networks, advancing science on risks like extreme heat, and partnering globally to ensure communities benefit from robust, health‑focused climate solutions.

https://wellcome.org/

Republic Power Group Limited Announces 1-For-20 Reverse Share Split

By
Advertorial Desk
-

SINGAPORE, Feb. 20, 2026 /PRNewswire/ — Republic Power Group Limited (NASDAQ: RPGL), today announced that it will effect a reverse share split of its Class A ordinary shares, par value $0.000625 per share (the “Class A Ordinary Shares”) and Class B ordinary shares, par value $0.000625 per share (the “Class B Ordinary Shares”), at a ratio of 1-for-20, to be effective at the open of business on February 23, 2026.

Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market (“Nasdaq”) on February 23, 2026. There is no public market for our Class B Ordinary Shares. Following the reverse share split, the Class A Ordinary Shares will have a new par value of $0.0125 per share and will continue to trade on Nasdaq under the symbol “RPGL” with the new CUSIP number, G7523E113. The reverse share split is expected to lead the Company’s Class A Ordinary Shares to trade at approximately 20 times the price per share at which it trades prior to the effectiveness of the reverse share split. The Company, however, cannot assure that the price of its Class A Ordinary Shares after the reverse split will reflect the 1-for-20 reverse split ratio, that the price per share following the effective time of the reverse split will be maintained for any period of time, or that the price will remain above the pre-split trading price. The reverse share split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per Class A Ordinary Share for continued listing on Nasdaq.

No fractional shares will be issued in connection with the reverse share split and all such fractional interests will be rounded up to the nearest whole number of Class A Ordinary Shares.

The reverse share split will reduce the number of issued and outstanding shares of the Company’s Class A Ordinary Shares from 62,025,000 to approximately 3.1 million shares, subject to any adjustments resulting from the treatment of the fractional shares.

On February 2, 2026, the board of directors of the Company approved the reverse share split of the Class A Ordinary Shares and Class B Ordinary Shares, at a ratio of 1-for-20.

Transhare Corporation is acting as the exchange agent and paying agent for the reverse share split. Shareholders holding their shares in book-entry form or in brokerage accounts need not take any action in connection with the reverse share split.

Transhare Corporation will provide instructions to any shareholders with certificates regarding the process in connection with the exchange of pre-reverse share split share certificates for ownership in book-entry form or share certificates on a post-reverse share split basis. Shareholders are encouraged to contact their bank, broker or custodian with any procedural questions.

About Republic Power Group Limited

Republic Power Group Ltd. is a Singapore-based company engaged in developing customized enterprise resource planning (“ERP”) software solutions, consulting and technical support services, and peripheral hardware.

For more information on our latest innovations and developments, visit https://republicpower.net/.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company’s goals and strategies; the Company’s future business development; the Company’s future acquisition opportunities; the Company’s ability to identify any acquisition opportunities that fit with our business strategies; the Company’s ability to consummate an attractive acquisition and realize the benefits of such transaction; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

 

1...1,2281,2291,230...6,718Page 1,229 of 6,718